JP2022511788A5 - - Google Patents
Info
- Publication number
- JP2022511788A5 JP2022511788A5 JP2021530816A JP2021530816A JP2022511788A5 JP 2022511788 A5 JP2022511788 A5 JP 2022511788A5 JP 2021530816 A JP2021530816 A JP 2021530816A JP 2021530816 A JP2021530816 A JP 2021530816A JP 2022511788 A5 JP2022511788 A5 JP 2022511788A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- individual
- composition according
- period
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024195531A JP2025024035A (ja) | 2018-11-30 | 2024-11-08 | S1p1受容体に関連する状態を治療する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773936P | 2018-11-30 | 2018-11-30 | |
| US62/773,936 | 2018-11-30 | ||
| US201962850464P | 2019-05-20 | 2019-05-20 | |
| US62/850,464 | 2019-05-20 | ||
| PCT/US2019/063413 WO2020112880A1 (en) | 2018-11-30 | 2019-11-26 | Methods of treating conditions related to the s1p1 receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024195531A Division JP2025024035A (ja) | 2018-11-30 | 2024-11-08 | S1p1受容体に関連する状態を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022511788A JP2022511788A (ja) | 2022-02-01 |
| JP2022511788A5 true JP2022511788A5 (cg-RX-API-DMAC7.html) | 2022-12-05 |
Family
ID=68966033
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021530816A Withdrawn JP2022511788A (ja) | 2018-11-30 | 2019-11-26 | S1p1受容体に関連する状態を治療する方法 |
| JP2024195531A Pending JP2025024035A (ja) | 2018-11-30 | 2024-11-08 | S1p1受容体に関連する状態を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024195531A Pending JP2025024035A (ja) | 2018-11-30 | 2024-11-08 | S1p1受容体に関連する状態を治療する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220023258A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3886841A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022511788A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102824401B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN118649163A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019387212A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3120706A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL283414A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020112880A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2528894A1 (en) | 2010-01-27 | 2012-12-05 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| CA3002540C (en) | 2015-01-06 | 2023-11-07 | Arena Pharmaceuticals, Inc. | Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor |
| JP6838744B2 (ja) | 2015-06-22 | 2021-03-03 | アリーナ ファーマシューティカルズ, インコーポレイテッド | S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩 |
| KR20190113955A (ko) | 2017-02-16 | 2019-10-08 | 아레나 파마슈티칼스, 인크. | 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법 |
| CN110520124A (zh) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
| JP7397011B2 (ja) | 2018-06-06 | 2023-12-12 | アリーナ ファーマシューティカルズ, インコーポレイテッド | S1p1受容体に関連する状態を治療する方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104311472B9 (zh) * | 2008-07-23 | 2020-03-17 | 艾尼纳制药公司 | 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物 |
| EP2528894A1 (en) | 2010-01-27 | 2012-12-05 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| WO2013116657A1 (en) * | 2012-02-03 | 2013-08-08 | Teva Pharmaceutical Industries Ltd. | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY |
| RU2016147569A (ru) * | 2014-05-09 | 2018-06-13 | Ногра Фарма Лимитед | Способы лечения воспалительного заболевания кишечника |
| CA3002540C (en) * | 2015-01-06 | 2023-11-07 | Arena Pharmaceuticals, Inc. | Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor |
| WO2017055611A2 (en) * | 2015-09-30 | 2017-04-06 | Nogra Pharma Limited | Methods of using smad7 antisense oligonucleotides based on biomarker expression |
| CN110520124A (zh) * | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
-
2019
- 2019-11-26 JP JP2021530816A patent/JP2022511788A/ja not_active Withdrawn
- 2019-11-26 KR KR1020217019803A patent/KR102824401B1/ko active Active
- 2019-11-26 AU AU2019387212A patent/AU2019387212A1/en not_active Abandoned
- 2019-11-26 US US17/299,741 patent/US20220023258A1/en not_active Abandoned
- 2019-11-26 EP EP19824097.0A patent/EP3886841A1/en active Pending
- 2019-11-26 CN CN202410692934.XA patent/CN118649163A/zh active Pending
- 2019-11-26 WO PCT/US2019/063413 patent/WO2020112880A1/en not_active Ceased
- 2019-11-26 CA CA3120706A patent/CA3120706A1/en active Pending
- 2019-11-26 CN CN201980087042.4A patent/CN113226307A/zh active Pending
-
2021
- 2021-05-25 IL IL283414A patent/IL283414A/en unknown
-
2024
- 2024-11-08 JP JP2024195531A patent/JP2025024035A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111132675B (zh) | 胆汁淤积性瘙痒的治疗 | |
| JP2022516662A5 (cg-RX-API-DMAC7.html) | ||
| JP2505944B2 (ja) | (S)―α―フルオロメチル―ヒスチジン及びそのエステルを含有するぜん息治療用医薬組成物 | |
| JP4938905B2 (ja) | 選択的s1p1レセプターアゴニストの投与法 | |
| US20200323843A1 (en) | Use of levocetirizine and montelukast in the treatment of viral infection caused by coronavirus | |
| JP2015526458A5 (cg-RX-API-DMAC7.html) | ||
| JP2002542287A (ja) | 医 薬 | |
| KR20200131816A (ko) | 캡시드 조립 조절제 투약 요법 | |
| JP2023549849A5 (cg-RX-API-DMAC7.html) | ||
| US11883410B2 (en) | Preventative and therapeutic agents for sarcopenia | |
| CN115702143A (zh) | 治疗系统性硬化症的方法 | |
| KR20170118830A (ko) | 조현병의 치료를 위한 일로페리돈 | |
| JP2024084670A5 (cg-RX-API-DMAC7.html) | ||
| US11666587B2 (en) | Veterinary composition comprising torasemide for the treatment of pulmonary edema associated with heart failure in domestic animals | |
| JP4384435B2 (ja) | くしゃみ抑制組成物 | |
| WO2019004465A1 (ja) | ペマフィブラートを含有する医薬 | |
| JP2022550458A5 (cg-RX-API-DMAC7.html) | ||
| WO2005063253A1 (ja) | アレルギー症状治療用医薬組成物 | |
| JP2010111667A (ja) | フェキソフェナジン又はエバスチンを含有する鎮咳及び/又は去痰のための医薬組成物 | |
| JP2024539735A5 (cg-RX-API-DMAC7.html) | ||
| RU2021123406A (ru) | Способы лечения состояний, связанных с рецептором s1p1 | |
| JP2020105081A (ja) | 遅発相アレルギー反応抑制剤 | |
| JP2000290198A (ja) | 鼻腔抵抗上昇等の抑制剤 | |
| HK1199815B (en) | Levocetirizine and montelukast for the treatment of influenza and common cold | |
| JP2003512293A (ja) | 腸炎のための抗炎症薬を製造するためにアムトルメチングアシルの使用 |